Ionis Makes RNA Therapeutics Collaboration Deal With Suzhou Ribo Life Science Co., Ltd.


Ionis Pharmaceuticals (IONS -0.6%) inks a collaboration and license agreement with Kunshan City-based Suzhou Ribo Life Science Co., Ltd. to develop and commercialize RNA-targeted therapeutics in China.

Under the terms of the deal, Ionis grants the rights to two Generation 2+ antisense drugs to Ribo for metabolic disease and cancer and an option to license a third Generation 2+ candidate. Ribo will be responsible for conducting a multi-year research and drug discovery program to identify drugs based on Ionis’ ssRNAi technology.

Ionis retains all rights to develop and commercialize ssRNAi and all drugs under the collaboration ex-China. It will also receive an undisclosed upfront payment, milestones, sales-based royalties and Ribo equity.

Ribo will pay a license fee for each drug candidate chosen for development and will be responsible for all development and commercialization costs in China. It will provide Ionis a royalty-free license to the data and IP created under the partnership.

Editorial Team

Our Editorial Team curates "news you can use" from hundreds of local newspapers, magazines, blogs and online sources, press releases, radio and TV news shows from around the world. We take great pride in being providing Daily Business Intelligence that's all business and no politics.